A Multicenter, Multiomics, Non-interventional, Real-world Study of the Efficacy and Safety of Immune Checkpoint Inhibitors as First-line Therapy for Advanced Malignancies

Xinqiao Hospital of Chongqing1 site in 1 country120 target enrollmentAugust 10, 2023

ConditionsMalignant Tumor Immunotherapy Artificial Intelligence

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Malignant Tumor
Sponsor: Xinqiao Hospital of Chongqing
Enrollment: 120
Locations: 1
Primary Endpoint: Progression-free survival
Status: Recruiting
Last Updated: 9 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy

Registry

clinicaltrials.gov

Start Date

August 10, 2023

End Date

December 31, 2025

Last Updated

9 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Xinqiao Hospital of Chongqing

Responsible Party

Principal Investigator

Jianguo Sun

Deputy director of oncology department，clinical professor

Xinqiao Hospital of Chongqing

Eligibility Criteria

Inclusion Criteria

•Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.
•the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology.
•the stage IV according to the eighth edition of IASLC.
•PS 0-2, the expected survival \> 3 months.
•the age of 18-75 years.
•no contraindication to treatment with immune checkpoint inhibitors.

Exclusion Criteria

•the patients' compliance was poor, which violated the rules of the trial;
•the patients with severe dysfunction of vital organs (heart, liver and kidney) ;
•the patients with other malignant tumors;
•the researchers considered that the patients should not participate in other conditions of the trial.